PMID- 28819375
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 8
IP  - 10
DP  - 2017
TI  - Bone Marrow Derived Mesenchymal Stem Cells Involve in the Lymphangiogenesis of 
      Lung Cancer and Jinfukang Inhibits the Involvement In Vivo.
PG  - 1786-1794
LID - 10.7150/jca.17859 [doi]
AB  - Lymphangiogenesis plays an important role in cancer metastasis. Bone 
      marrow-derived mesenchymal stem cells (BMMSCs) migrate to the site of 
      tumorigenesis and in turn promote the metastasis. However, whether BMMSCs involve 
      in the lymphangiogenesis of lung cancer is unclear. Jinfukang has clinically been 
      used for the treatment of non small cell lung cancer (NSCLC) in China. In this 
      study, to investigate the involvement of BMMSCs in lymphangiogenesis in lung 
      cancer, and evaluate the inhibitory effect of Jinfukang on the lymphangiogenesis, 
      chimeric mice were prepared by transplanting bone marrow from green fluorescent 
      protein (GFP) transgenic mice (C57BL/6-EGFP) into irradiated C57BL/6 mice. Then, 
      the chimeric mice were injected subcutaneously with freshly prepared Lewis lung 
      carcinoma cell suspension to make lung tumor model, and the model mice were 
      further orally administrated with Jinfukang once per day for 3 weeks. Four weeks 
      after the bone marrow transplantation, GFP-positive cells primarily existed in 
      bone marrow of acceptor mice, and three more weeks after, Lewis lung carcinoma 
      cells formed a tumor mass in chimeric mice. Observation of GFP-positive cells 
      revealed that BMMSCs transferred into the lung tumor. Immunofluorescent analyses 
      of lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), a lymphatic 
      endothelium marker, demonstrated a part of lymphatic endothelial cells in lung 
      cancer were derived from BMMSCs, and those lymphatic endothelial cells 
      contributed to the lung tumor lymphangiogenesis. Furthermore, Jinfukang treatment 
      resulted in a significant reduction of the average weight of the tumor mass in 
      chimeric mice, and displayed a significant lower number of LYVE-1 positive cells. 
      The present results suggest that BMMSCs transfer to tumor, differentiate into 
      lymphatic endothelial cells, and involve in the lymphangiogenesis in lung cancer 
      of mice. Jinfukang inhibits the lung tumor mass via suppression of the BMMSCs 
      transformation and lung tumor lymphangiogenesis. Our findings might provide the 
      potential for the cancer therapies.
FAU - Zhou, Xian-Mei
AU  - Zhou XM
AD  - Department of Respiratory Medicine, Jiangsu Province Hospital of Traditional 
      Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing 210029, PR China.
FAU - Wang, Dan
AU  - Wang D
AD  - Department of Respiratory Medicine, Jiangsu Province Hospital of Traditional 
      Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing 210029, PR China.
FAU - He, Hai-Lang
AU  - He HL
AD  - Department of Respiratory Medicine, Jiangsu Province Hospital of Traditional 
      Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing 210029, PR China.
FAU - Tang, Jie
AU  - Tang J
AD  - Department of Respiratory Medicine, Jiangsu Province Hospital of Traditional 
      Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 
      Nanjing 210029, PR China.
FAU - Wu, Jing
AU  - Wu J
AD  - State Key Laboratory of Analytical Chemistry for Life Science and Collaborative 
      Innovation Center of Chemistry for Life Sciences, Jiangsu Key Laboratory of 
      Advanced Organic Materials, School of Chemistry and Chemical Engineering, Nanjing 
      University, Nanjing, 210023, PR China.
FAU - Xu, Ling
AU  - Xu L
AD  - Tumor Institute of Traditional Chinese Medicine, Longhua Hospital, Shanghai 
      University of Traditional Chinese Medicine, Shanghai 200032, PR China.
FAU - Li, Jian-Xin
AU  - Li JX
AD  - State Key Laboratory of Analytical Chemistry for Life Science and Collaborative 
      Innovation Center of Chemistry for Life Sciences, Jiangsu Key Laboratory of 
      Advanced Organic Materials, School of Chemistry and Chemical Engineering, Nanjing 
      University, Nanjing, 210023, PR China.
LA  - eng
PT  - Journal Article
DEP - 20170701
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC5556641
OTO - NOTNLM
OT  - Jinfukang
OT  - bone marrow-derived mesenchymal stem cells
OT  - chimeric mice
OT  - lung cancer
OT  - lymphangiogenesis
COIS- Competing Interests: The authors declare that they have no competing interests to 
      disclose.
EDAT- 2017/08/19 06:00
MHDA- 2017/08/19 06:01
PMCR- 2017/01/01
CRDT- 2017/08/19 06:00
PHST- 2016/10/09 00:00 [received]
PHST- 2017/04/08 00:00 [accepted]
PHST- 2017/08/19 06:00 [entrez]
PHST- 2017/08/19 06:00 [pubmed]
PHST- 2017/08/19 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - jcav08p1786 [pii]
AID - 10.7150/jca.17859 [doi]
PST - epublish
SO  - J Cancer. 2017 Jul 1;8(10):1786-1794. doi: 10.7150/jca.17859. eCollection 2017.